• If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease)
  • Filing acceptance is based on the Phase III METEOROID study showing that Enspryng reduced the risk of relapses by 68%
  • MOGAD is a rare disease of the central nervous system characterized by unpredictable attacks of the optic nerves, spinal cord or brain